Tarsus to Present at Upcoming Investor Conferences
August 30 2023 - 3:30PM
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to
focus on unmet needs and apply proven science and new technology to
revolutionize treatment for patients, starting with eye care, today
announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer
and Chairman, and Jeff Farrow, Chief Financial and Strategy
Officer, will participate in the following conferences, both
located in New York City, NY:
- H.C. Wainwright 25th Annual Global Investment Conference
- Jeff Farrow, Chief Financial and Strategy Officer, will
participate in an in-person Fireside Chat on Monday, September 11,
2023, at 9:30am PT / 12:30pm ET
- Morgan Stanley 21st Annual Global Healthcare Conference
- Bobak Azamian, M.D., Ph.D., Chief Executive Officer and
Chairman, and Jeff Farrow, Chief Financial and Strategy Officer,
will conduct in-person one-on-one meetings on Tuesday, September
12, 2023
All dates and times listed above are subject to change. Details
on presentation times or changes to presentation dates can be found
on the Company's website. Please
check www.tarsusrx.com for the latest information.
A live webcast of the presentation will also be available on
the events section of the Tarsus website. The replay will
be available within 48 hours and will be archived for a limited
time.
About Tarsus Pharmaceuticals,
Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new
technology to revolutionize treatment for patients, starting with
eye care. XDEMVY (lotilaner ophthalmic solution) 0.25% is FDA
approved in the United States for the treatment of Demodex
blepharitis. Tarsus is also advancing its pipeline to address
several diseases with high unmet need across a range of therapeutic
categories, including eye care, dermatology, and infectious disease
prevention. Tarsus is studying three investigational medicines in
clinical trials, including TP-03 for the treatment of Meibomian
Gland Disease, which is currently being studied in a Phase 2a
clinical trial, TP-04 for the potential treatment of Rosacea and
TP-05, an oral tablet for the prevention of Lyme disease. TP-04 and
TP-05 are both currently being studied in Phase 2a clinical trials
to evaluate safety, tolerability, and proof-of activity.
Media
Contact: |
Adrienne Kemp |
Sr. Director, Corporate
Communications |
(949) 922-0801 |
AKemp@tarsusrx.com |
|
Investor
Contact: |
David Nakasone |
Head of Investor
Relations |
(949) 620-3223 |
DNakasone@tarsusrx.com |
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Apr 2024 to May 2024
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From May 2023 to May 2024